glp 1 agonist vs sglt2 inhibitor inhibitors or GLP-1 receptor agonists as second-line therapy in | VHRM Complementary Yet Distinct Roles of

Main GLP1 and Related Brands Leading GLP-1 medications in 2025 include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss), liraglutide (Victoza for diabetes, Saxenda for weight loss), tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), dulaglutide (Trulicity for diabetes) and oral semaglutide (Rybelsus)

Monami et al evaluated changes in lipid levels with GLP-1RA versus placebo in a meta-analysis

This study supports the ongoing monitoring of tirzepatide to ensure its safe use in clinical settings [17]

45,46 As shown in Figure 2 , GLP-1RAs penetrate the blood-brain barrier and directly activate GLP-1 receptors in the hypothalamus, especially within the ARH nucleus, a key center for appetite regulation

Beyond tirzepatide and retatrutide, Eli Lilly is also investing in oral GLP-1 therapies ( orforglipron ), aiming to provide convenient, effective alternatives to injections